Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.45 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114833 | 0.90 | MRGPRX4 (0.53) | MRGPRX4MAOBPTGER1PPIAPTGDR2 | |
| Hydrochloric Acid SCHEMBL7526696 | 0.89 | MRGPRX4 (0.52) | MRGPRX4MAOBPTGER1PPIAPTGDR2 | |
| SCHEMBL7117529 | 0.87 | MRGPRX4 (0.53) | MRGPRX4MAOBPTGER1PPIAPTGDR2 | |
| SCHEMBL6834962 | 0.85 | MRGPRX4 (0.50) | MRGPRX4MAOBPTGER1PPIAPTGDR2 | |
| SCHEMBL6555786 | 0.81 | MAOB (0.51) | MRGPRX4MAOBPTGER1 | |
| SCHEMBL6490916 | 0.81 | MRGPRX4 (0.50) | MRGPRX4MAOBPTGER1PPIAPTGDR2 | |
| SCHEMBL6323971 | 0.80 | MRGPRX4 (0.49) | MRGPRX4MAOBPTGER1PPIAPTGDR2 | |
| Hydrochloric Acid SCHEMBL6834965 | 0.79 | MRGPRX4 (0.48) | MRGPRX4MAOBPTGER1PPIAPTGDR2 | |
| SCHEMBL6330912 | 0.78 | MRGPRX4 (0.48) | MRGPRX4MAOBPTGER1PPIACYP19A1 | |
| SCHEMBL5098912 | 0.77 | MRGPRX4 (0.54) | MRGPRX4MAOBPTGER1PPIAPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1360170-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | MRGPRX4 3149/4885MAOB 1337/4885PTGER1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.